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Abstract
Background: Stenotrophomonas maltophilia is an important nosocomial pathogen. This pathogen has intrinsic or
acquired resistance to a number of antibiotics classes. Furthermore, Stenotrophomonas infections have been associated
with high mortality, mainly in immunocompromised patients. Accordingly, we conducted a retrospective cohort study
on the clinical data, microbiological characteristics, and outcomes of patients with S. maltophilia (SM) bacteremia.
Methods: A retrospective cohort study was conducted at two tertiary care referral hospitals in Seoul, South Korea. Data
were collected between January 2006 and December 2015 from electric medical records. Our analysis aimed to identify
the risk factors associated with crude mortality, as well as the predictive factors of quinolone-resistant strains
in SM bacteremia patients.
Results: A total of 126 bacteremia patients were enrolled in the study. The mortality rate was 65.1%. On
multivariable analysis, hypoalbuminemia (odds ratio [OR], 5.090; 95% confidence interval [CI], 1.321–19.621; P =
0.018), hematologic malignancy (OR, 35.567; 95% CI, 2.517–502.515; P = 0.008) and quinolone-resistant strains
(OR, 7.785; 95% CI, 1.278–47.432; P = 0.026) were independent risk factors for mortality. Alternatively, usage of
an empirical regimen with quinolone (OR, 0.172; 95% CI, 0.034–0.875; P = 0.034) was an independent protective factor
for mortality. The multivariable analysis of predictive factors revealed that high Charlson comorbidity index (OR, 1.190;
95% CI, 1.040–1.361; P = 0.011) and indwelling of a central venous catheter (CVC) (OR, 3.303; 95% CI, 1.194–9.139; P =
0.021) were independent predisposing factors associated with quinolone-resistant strains in SM bacteremia patients.
Conclusions: Our findings suggest that a high Charlson comorbidity score and indwelling of a CVC were significantly
independent predictors of quinolone-resistant strains in SM bacteremia patients. Therefore, we need to carefully consider
the antibiotic use in SM bacteremia patients with these predictive factors.
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Background
Stenotrophomonas maltophilia is a non-fermentative,
gram-negative bacillus that is closely related to the Pseudo-
monas species. Bacterium bookeri, now known as S. malto-
philia (SM), was first isolated in 1943 and was subsequently
classified as a member of the genus Pseudomonas in 1961.
Thereafter, it was classified as a member of Xanthomonas
genus in 1983, and finally it came to rest in the Stenotro-
phomonas genus in 1993 [1]. SM is a bacterium that can
occur in almost any aquatic or humid environment [2], and
is not considered to be a highly virulent pathogen. Over the
last decade, SM has risen to prominence as an important
nosocomial pathogen associated with significant case/fatal-
ity ratios in certain patient populations, particularly in indi-
viduals who are severely debilitated or immunosuppressed
[3–5]. Pneumonia and bacteremia are the most common
manifestations of SM infection [6]. However, treatment of
SM bacteremia is challenging due to the resistance of SM
to many broad-spectrum antimicrobial agents. Moreover,
SM exhibits high-level intrinsic resistance to a variety of
structurally unrelated antibiotics, including: beta-lactams,
quinolones, aminoglycosides, tetracycline, disinfectants,
and heavy metals [7, 8]. Furthermore, it can acquire re-
sistance through the uptake of resistance genes located
on integrons, transposons, and plasmids via horizontal
gene transfer and mutations [9, 10]. Thus, choosing the
optimal antibiotic for the treatment of SM bacteremia is
very difficult. Trimethoprim-sulfamethoxazole (TMP-
SMX) should be considered as the empirical choice for
clinically suspected SM infections and as the treatment
of choice for culture-proven infections by this agent [11,
12]. However, due to concerns regarding adverse events
related to TMP-SMX treatment, levofloxacin has also
been used as an alternative option [13, 14]. Fluoroquino-
lone and SMX monotherapies may be equally effective
for the treatment of SM infections [15]. But, the overuse
of quinolones worldwide has resulted in higher resist-
ance rates in SM [16–18]. Therefore, we investigated
the predictive factors of quinolone-resistant strains in
SM bacteremia patients.
Methods
Study population and design
A retrospective cohort study was conducted at two ter-
tiary care referral hospitals in Seoul, South Korea. Data
were collected between January 2006 and December
2014 from digital medical records. Patients 18 years or
older with 1 or more positive blood cultures of SM that
met the Centers for Disease Control and Prevention
(CDC) criteria for blood stream infection (BSI) [19],
were eligible for inclusion. If a patient had multiple epi-
sodes of bacteremia, only the data from the first episode
were included.
Definitions
SM bacteremia was defined by the presence of a blood
culture that yielded SM from one or more collected blood
samples between January 2006 and December 2014. The
source of bacteremia was determined clinically on the
basis of the presence of an active site of infection as deter-
mined by chart review or isolation of the organism from
other clinical specimens coincident with the episode of
bacteremia. Polymicrobial bacteremia was defined by the
isolation of an additional pathogen satisfying CDC criteria
for BSI [19] within 24 h of index SM isolate. Healthcare-
associated and community-acquired bacteremia were de-
fined according to the CDC criteria for BSI [19]. Empiric
antibiotic therapy was defined as the therapy initiated be-
fore the report of antibiotic susceptibility results, whereas
definitive therapy was defined as the therapy given after
the report of antibiotic susceptibility [20]. Chronic kidney
disease was defined an estimated glomerular filtration rate
(eGFR) (MDRD equation) of < 60mL/min per 1.73m2
without renal replacement therapy. End stage renal disease
was defined as an eGFR (MDRD equation) of < 15mL/
min per 1.73m2 with renal replacement therapy. Pulmon-
ary disease was defined as chronic obstructive lung disease
or asthma. Appropriate antimicrobial therapy was defined
as the administration of at least one agent to which the
index SM isolate was susceptible in vitro. Immunosup-
pressive therapy was defined as a daily ≥20mg dose of a
prednisolone-equivalent steroid, monoclonal antibodies,
antimetabolite drugs, or T-cell inhibitors within 30 days
prior to bacteremia onset. Neutropenia was defined as an
absolute neutrophil count of < 500/mm3 at the onset of
bacteremia. Thrombocytopenia was defined as a platelet
count of less than 100,000/mL, and hypoalbuminemia was
defined as an albumin count of less than 3 g/dL at the
time of bacteremia. Mortality by SM bacteremia was de-
fined as death within 60 days after the bacteremia isolation
with no other apparent cause of death.
Data collection
A trained examiner used a electric medical record to
collect demographic data. Data elements included demo-
graphics, length of hospital stay before SM bacteremia
(days), source of bacteremia, antibiotics-susceptibility of
the isolated pathogen, antimicrobial therapy regimen,
past medical history, comorbid conditions, surgery, prior
chemotherapy/radiation therapy, or receipt of immuno-
suppressive medications (each 30 days). The data included
appropriateness of antibacterial therapy, existence of in-
dwelling medical devices before SM bacteremia during
hospitalization, removal of previously present CVC, and
length of stay in ICU and hospital (days). The degree of
comorbidity was quantified using the Charlson comorbid-
ity index [21] and the severity of illness was assessed by
the Acute Physiology and Chronic Health Evaluation II
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(APACHE II) score. Laboratory data and outcomes were
also recorded.
In vitro antimicrobial susceptibility testing
All bacterial species were identified using conventional
methods and/or the ATB 32GN system (bioMerieux,
Marcy l’Etoile, France). Antimicrobial susceptibility tests
were performed using the disk diffusion method or a
VITEK-2N131 card (bioMerieux, Hazelwood, MO, USA).
The results were interpreted based on the Clinical and
Laboratory Standards Institute (CLSI) guidelines [22]. SM
isolates resistant to TMP-SMX were defined to have a
minimal inhibitory concentration (MIC) ≥4/76mg/mL to
TMP-SMX. SM isolates which were resistant to levofloxa-
cin (MIC ≥8mg/mL) or those with intermediate resistance
(MIC = 4mg/mL) to levofloxacin were defined as quin-
olone-resistant strains.
Statistical analysis
All statistical analyses were performed using SPSS for
Windows (ver. 23.0, SPSS Inc., Chicago, IL, USA). The
statistical analyses were performed to assess the factors
associated with crude mortality and quinolone suscepti-
bility. Continuous variables were expressed as mean ±
standard deviation (SD), and categorical variables were
expressed as a number (percentage). The Kolmogorov-
Smirnov test was used to analyze the normality of the
distribution of parameters. Data that did not show nor-
mal distributions were expressed as median and inter-
quartile ranges (IQR). The Student’s t-test was used for
continuous variables and the Chi-square test or Fisher’s
exact test was used for categorical variables. Variables
that did not show normal distributions were compared
using the Mann-Whitney test or Kruskal-Wallis test.
Univariate and multivariable logistic regression was used
to evaluate the risk factors of mortality and the predict-
ive factors of quinolone-resistant strains. Variables with
p-values of less than 0.10 in univariate analyses were
included in a multivariable logistic regression analysis to
identify the risk factors associated with mortality and the
predictive factors of quinolone-resistant strains. Results
from the multivariate analysis are expressed as an odds
ratio (OR) and 95% confidence interval (CI). All statis-
tical tests were two-tailed and a P value of less than 0.05
was considered to be statistically significant.
Results
Baseline characteristics of SM bacteremia patients and
comparison of clinical characteristics and outcomes
During the study period, 126 bacteremia patients were
enrolled. The mean age of the patients was 61.22 ±
15.07 years and the 68.3% (86/126) of the patients were
men. The mean length of stay in the hospital before the
occurrence of SM bacteremia was 57.1 ± 22.5 days. The
mean Charlson comorbidity index score was 6.5 ± 3.2
and the median APACHE II score was 13.0 (IQR, 9–19).
Bivariable analyses were performed to investigate the
risk factors of mortality in SM bacteremia patients.
Table 1 shows a comparison of survivors and non-survi-
vors during the entire hospitalization period. Univariate
analyses, showed that hematologic malignancy (P =
0.005), indwelling of hemodialysis catheter (P = 0.028),
high APACHE II scores (P = 0.001), hypoalbuminemia
(P = 0.003), thrombocytopenia (P = 0.004), and low
hemoglobin concentration (P = 0.035) were associated
with mortality. Also, the length of stay before bacteremia
was longer in non-survivors (P = 0.038).
Anatomic origin and microbiologic findings of SM
bacteremia are presented in Table 2. Catheter-related
infection was the most common primary source of
bacteremia (49 cases, 38.9%), followed by intra-abdomen
infection (38 case, 30.2%) and respiratory infection (35
case, 27.8%). The rate of CVC removal was 59.3% (54/
91). In our study, 11.9% (15/126) of patients had SM
strains resistant to TMP/SMX, and 31.2% (39/126) had
strains resistant to quinolone. Only 21 patients (16.7%)
were using an empirical regimen with quinolone and
there were no cases using an empirical regimen with
TMP/SMX. The number of patients under a definitive
regimen with quinolone was 32% (40/126), and with
TMP/SMX it was 24.8% (31/126).
Mortality risk factors in SM bacteremia patients
On multivariable analysis, hypoalbuminemia (OR, 5.090;
95% CI, 1.321–19.621; P = 0.018), hematologic malig-
nancy (OR, 35.567; 95% CI, 2.517–502.515; P = 0.008)
and quinolone-resistant strains (OR, 7.785; 95% CI,
1.278–47.432; P = 0.026) were independent risk factors
for mortality. Contrary, usage of an empirical regimen
with quinolone (OR, 0.172; 95% CI, 0.034–0.875; P =
0.034) was independent protective factors for mortality
(Table 3).
Predicting factors for SM bacteremia with quinolone-
resistant strains
Analyses of predictive factors for SM bacteremia with
quinolone-resistant strains were performed (Table 4).
One patient died immediately on the day of bacteremia
and was excluded from this analysis due to death not re-
lated to antibiotic adequacy (N = 125 cases). On univari-
ate analysis, high Charlson comorbidity index and long
lengths of hospital stay before the onset of bacteremia
were significant related factors (P = 0.030 and P = 0.015).
Indwelling of CVC, ventilator, and Foley catheter were
additional risk factors. Quinolone-resistant SM patients had
a significantly higher mortality than the quinolone sensitive
group (P = 0.001 and P = 0.013). Based on this multivariable
analysis, the Charlson comorbidity index (OR, 1.190; 95%
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Table 1 Baseline characteristics of patients with S. maltophilia bacteremia
Factors Survivors N = 44 Non-survivors
N = 82
p value
Age, y, mean ± SD 71.0 (60.5–79) 74.5 (61.0–80.25) 0.310
Age ≥ 65 years, n(%) 24 (54.5) 34 (41.5) 0.160
Male, n (%) 33 (75.0) 53 (64.6) 0.233
BMI, kg/m2, median (IQR) 21.7 (19.4–25.0) 21.9 (19.0–24.4) 0.847
Comorbidities
HTN, n (%) 15 (34.1) 32 (39.0) 0.585
DM, n (%) 16 (36.4) 23 (28.0) 0.336
Cardiovascular disease, n (%) 9 (20.5) 13 (15.9) 0.517
Chronic kidney diseasea, n (%) 4 (9.1) 4 (4.9) 0.449
End stage renal disease, n (%) 1 (2.3) 7 (8.5) 0.259
Chronic liver disease, n (%) 5 (11.4) 11 (13.4) 0.742
Pulmonary disease, n (%) 4 (9.1) 8 (9.8) 1.000
Solid tumor, n (%) 18 (40.9) 43 (52.4) 0.217
Hematologic malignancy, n (%) 1 (2.3) 17 (20.7) 0.005
Solid organ transplantation, n (%) 3 (6.8) 4 (4.9) 0.694
Charlson score, mean ± SD 5.7 ± 3.0 6.9 ± 3.2 0.049
Predisposing factors
Chemotherapy, n (%) 4 (9.1) 10 (12.2) 0.769
Major surgerya, n (%) 15 (34.9) 29 (35.4) 0.957
ICU care, n (%) 29 (65.9) 54 (65.9) 0.995
Length of stay in hospital before
bacteremia (days), median (IQR)
12.0 (3.5–24.5) 26.0 (14.0–56.0) 0.038
Central venous catheter, n (%) 31 (70.5) 59 (72.8) 0.777
Hemodialysis catheter, n (%) 2 (4.5) 15 (18.8) 0.028
Mechanical ventilator, n (%) 19 (43.2) 41 (50.6) 0.427
Foley catheter, n (%) 28 (63.6) 47 (58.0) 0.541
Clinical severity
Shock, n (%) 10 (22.7) 33 (40.2) 0.075
APACHE II score, mean ± SD 11.0 ± 5.8 15.4 ± 6.9 < 0.001
Laboratory findings
Neutropenia, n (%) 3 (6.8) 15 (18.3) 0.079
Hypoalbuminemia, n (%) 18 (6.8) 56 (18.3) 0.003
Thrombocytopenia, n (%) 9 (20.5) 38 (46.3) 0.004
Hemoglobin (g/L), mean ± SD 10.1 ± 1.6 9.4 ± 1.5 0.032
C-reactive protein (mg/L), median (IQR) 69.2 (32.2–129.5) 89.3 (58.5–148.0) 0.057
Estimated GFR (ml/min per 1.73m2),
median (IQR)
85.0 (54.2–98.0) 80.0 (44.0–104.0) 0.675
Hospital stay, days 53.0 (20.5–78.0) 60.0 (35.0–97.0) 0.137
Length of stay in ICU, days 30 (11.5–50.0) 39 (23.0–67.0) 0.640
Note. SD Standard deviation, BMI Body mass index, IQR Interquartile range, HTN Hypertension, DM Diabetes mellitus, ICU Intensive care unit, APACHE II Acute
Physiologic and Chronic Health Evaluation II score
a Major surgery, any surgical procedure that involves anesthesia or respiratory assistance
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CI, 1.040–1.361; P = 0.011) and indwelling of a CVC (OR,
3.303; 95% CI, 1.194–9.139; P = 0.021) were identified as in-
dependent predisposing factors associated with quinolone-
resistant strains in SM bacteremia patients.
Discussion
Among non-fermenting gram negative bacilli, SM has been
reported to be the third most commonly isolated pathogen
after Pseudomonas aeruginosa and Acinetobacter bauman-
nii [23]. Furthermore, SM bacteremia is associated with
high mortality rates, the crude mortality estimates range
from 21 to 69% [23]. Previous studies have reported that
risk factors associated with mortality for SM bacteremia
include indwelling of CVC in intensive care units, immuno-
compromising conditions, exposure to broad-spectrum
antibiotic therapy, and long hospital stays [3, 9, 23]. In our
study, the mortality rate of 65.1% was similar to the rate re-
ported in previous studies. Bivariable analyses to investigate
the risk factors of mortality in SM bacteremia, identified
hematologic malignancy and hypoalbuminemia as inde-
pendent risk factors. In addition, our results indicate that
quinolone resistance has an impact on mortality, and it has
also been shown that the use of empirical quinolone can re-
duce mortality after adjusting the analysis. There were also
statistical differences in crude (87.2% vs 55.8%, P = 0.001)
and attributable mortality (61.5% vs 30.6%, P = 0.001)
between quinolone-resistant and sensitive groups. Conse-
quently, we analyzed the risk factors associated with quin-
olone resistance in SM bacteremia. To our knowledge,
there are no reports investigating the risk factors for
Table 2 Anatomic origin and microbiologic findings of S. maltophilia bacteremia in study participants
Factors Survivors N = 44 Non-survivors N = 82 p value
Infection source
Pneumonia 12 (27.9) 23 (28.0) 0.987
Catheter-related infection 15 (34.1) 34 (42.0) 0.202
Intra-abdominal infection 16 (36.4) 22 (27.2) 0.285
Soft tissue infection 0 (0.0) 5 (6.2) 0.161
Urinary tract infection 1 (2.3) 0 (0.0) 0.352
Polymicrobial infection 18 (40.9) 36 (43.9) 0.746
Antibiotics susceptibility
Quinolone resistance 5 (11.6) 34 (41.5) 0.001
TMP-SMX resistance 3 (6.8) 12 (14.6) 0.197
Resistant straina 17 (38.6) 49 (59.8) 0.024
Treatment
Empirical antibiotic use
Cephalosporins 2 (4.5) 6 (7.4) 0.711
Carbapenems 13 (29.5) 42 (51.9) 0.016
Fluoroquinolones 13 (29.5) 8 (9.8) 0.004
BLBLIs 14 (31.8) 16 (19.5) 0.122
TMP-SMX 0 (0.0) 0 (0.0) –
Definitive antibiotic use
Carbapenems 2 (4.5) 16 (19.5) 0.022
Fluoroquinolones 21 (47.7) 19 (23.5) 0.005
BLBLIs 3 (6.8) 5 (6.2) 1.000
TMP-SMX 4 (9.1) 27 (33.3) 0.003
Inappropriate antimicrobial therapyb, yes 14 (31.8) 25 (30.9) 0.912
Note. BLBLIs Beta-lactam/beta-lactamase inhibitors, TMP-SMX Trimethoprim-sulfamethoxazole
The data were expressed as number (%) or median (interquartile range)
aResistant strain, Quinolone or/and TMP-SMX resistance
bAppropriate antimicrobial therapy, the administration of at least one agent to which the index SM isolate was susceptible in vitro
Table 3 Multivariate analysis for predictive factors for mortality
in patients with S. maltophilia bacteremia
Factors OR 95% CI P value
Hematologic malignancy 35.57 2.52–502.52 0.008
Hypoalbuminemia 5.09 1.32–19.62 0.018
Quinolone resistance 7.79 1.28–47.43 0.026
Empirical antibiotic - quinolone use 0.17 0.03–0.88 0.034
Note. OR Odds ratio, CI Confidence interval
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quinolone-resistant SM bacteremia. There have been stud-
ies of risk factors related to the acquisition of resistance to
levofloxacin in all clinical specimens and to quinolone sus-
ceptibility using only respiratory tract specimens with SM
[17, 24]. In respiratory tract specimens, a relative factor for
resistance to quinolone was the previous use of piperacillin/
tazobactam, and risk factors to levofloxacin resistance were
exposure to levofloxacin for more than 3weeks and co-
Table 4 Comparisons of Clinical characteristics between quinolone-susceptible and quinolone-resistant groups
Factors Susceptible group N = 86 Resistant group N = 39 p value
Age, years 63.0 (51.0–70.0) 66.0 (53.5–72.5) 0.215
Age ≥ 65 years, n(%) 37 (43.0) 20 (51.3) 0.390
Gender, male 57 (66.3) 29 (64.6) 0.233
Comorbidities
HTN 30 (34.9) 16 (41.0) 0.509
DM 29 (33.7) 10 (25.6) 0.366
Cardiovascular disease 13 (15.1) 9 (23.1) 0.279
Chronic kidney disease 6 (7.0) 2 (5.1) 1.000
End stage renal disease 4 (4.7) 4 (10.3) 0.255
Chronic liver disease 12 (14.0) 4 (10.3) 0.774
Pulmonary disease 8 (9.3) 4 (10.3) 1.000
Solid tumor 42 (48.8) 19 (48.7) 0.990
Hematologic malignancy 12 (14.0) 6 (15.4) 0.833
Solid organ transplantation 5 (5.8) 2 (5.1) 1.000
Charlson score 6.1 ± 3.1 7.4 ± 3.2 0.030
Predisposing factors
Chemotherapy 11 (12.8) 3 (7.7) 0.546
Major surgerya 28 (32.9) 16 (35.4) 0.382
ICU care 54 (62.8) 29 (74.4) 0.205
Hospital stay before bacteremia, days 17.0 (8.0–34.0) 30.0 (13.5–57.5) 0.015
Central venous catheter 57 (66.3) 32 (84.2) 0.019
Hemodialysis catheter 9 (10.5) 8 (21.6) 0.100
Mechanical ventilator 36 (41.9) 24 (63.2) 0.029
Foley catheter 47 (54.7) 28 (73.7) 0.046
Clinical findings
Shock 23 (26.7) 20 (51.3) 0.007
APACHE II score 13.0 (8.0; 18.0) 14.0 (11.0; 21.5) 0.115
Laboratory findings
Neutropenia 14 (16.3) 4 (10.3) 0.374
Hypoalbuminemia 52 (60.5) 21 (53.8) 0.487
Thrombocytopenia 28 (32.6) 19 (48.7) 0.084
Hemoglobin, g/L 9.8 ± 1.7 9.4 ± 1.3 0.296
C-reactive protein, mg/L 86.8 (41.5–142.5) 79.3 (44.5–153.0) 0.914
Estimated GFR, ml/min per 1.73m2 87.0 (51.0–101.0) 72.0 (45.4–106.0) 0.592
Outcomes
Inappropriate antimicrobial therapy 23 (26.7) 16 (42.1) 0.089
Hospital stay, days 50.0 (26.0–78.0) 68.0 (35.0–150.0) 0.054
Mortality 48 (55.8) 34 (87.2) 0.001
Note. HTN Hypertension, DM Diabetes mellitus, ICU Intensive care unit, APACHE II Acute Physiologic and Chronic Health Evaluation II score
The data were expressed as mean ± standard deviation, number (%), or median (interquartile range)
a Major surgery, any surgical procedure that involves anesthesia or respiratory assistance
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infection/co-colonization with Klebsiella pneumoniae re-
sistant to levofloxacin.
In this report, a high Charlson comorbidity index and
indwelling of CVC were independent risk factors associ-
ated with resistance to quinolone in SM bacteremia. The
Charlson comorbidity index is a widely used comorbidity
index [21]. A high CCI value means that many coexist-
ent diseases may directly or indirectly affect the choice
of antibiotics used and the outcome [25]. Especially, the
presence of many coexistent diseases suggests that the
previous use of antibiotics, or a prolonged history of
hospital admissions, provides opportunities for coexist-
ent diseases to develop. Furthermore, a high CCI value
is associated with a greater risk to acquire common anti-
biotic resistance. This may be due to previous antibiotic
uptake or hospital stays, however, this analysis was not
part of our study and further studies are needed.
Indwelling of CVC has already been shown to be sig-
nificantly associated with mortality and bacteremia in
previous literature [9]. In particular, removal of CVC has
been associated with reduced mortality [26–28]. How-
ever, removal of CVC did not influence mortality and
quinolone resistance in this report. It is estimated that
the rate of patients who adequately removed CVC was
only 40%, and therefore did not significantly affect the
outcome. SM has the ability to adhere on prosthetic
devices such as CVC and form a biofilm. Biofilms can
increase antibiotic resistance [11]. Therefore, indwelling
of CVC is a risk factor to biofilm formation and, accord-
ingly, to quinolone-resistance. Therefore, it is necessary
to actively encourage the removal of CVC.
Previous literature has proven the relationship between
inappropriate antimicrobial therapy and mortality in SM in-
fections [23, 27]. Although not relevant to this study, usage
of empirical quinolone had a significantly reduced mortality
risk. Empirical antibiotic regimens are determined by the
severity of patients. Therefore, patients that underwent an
empirical quinolone regimen were more likely to have low
SM severity and lower mortality. Overall, the periods of
empirical antibiotic use were short and there were no
patients using TMP / SMX empirically, so whether the
empirical use of quinolone actually had a significant impact
needs to be analyzed further. Also, SM infections may not
be an independent contributor to mortality increase, there-
fore inappropriate therapy should not have major effects on
the outcome of patients [29]. The rate of polymicrobial in-
fections in SM bacteremia was high in the previous litera-
ture [23] and in this study as well (42.8%). Thus, high
polymicrobial infections may be a confounding factor for
appropriate antibiotic use, and this may have affected the
mortality risk-factor analysis. Therefore, subgroup analysis
was performed in patients with polymicrobial infection.
However, there was no significant difference between the
two groups regarding mortality (Additional file 1: Table S1).
Significantly, the use of empirical or definitive treat-
ment of carbapenem was higher in the mortality group,
although it was not significant in the multivariate ana-
lysis. This suggests that the possibility of breakthrough
infections by SM in patients being treated with carba-
penem is due to intrinsically resistant carbapenem and
the selection pressure of SM should be considered [29,
30]. Only 24.8% of patients received TMP/SMX. A high
proportion of ICU care and polymicrobial infections
may have influenced antibiotic selection. Nevertheless,
careful use of carbapenem is necessary, and the possibil-
ity for breakthrough infections should be considered.
Our study had several limitations. First, the retrospective
design of this study was a major limitation. Second, the
history of previous antibiotic use and previous hospital
admissions were not investigated. This is especially im-
portant, since these are factors related to the acquisition
of antibiotic resistance. Third, we could not investigate
the susceptibility of other antibiotics except quinolone
and TMP/SMX, and our quinolone analysis was limited to
levofloxacin only.
Conclusion
Quinolone-resistant SM isolates have been emerging and
spreading in Korean hospitals, and current therapeutic
options are limited for SM bacteremia. Our results suggest
that a high Charlson comorbidity index and indwelling of
CVC were significant independent predictors of SM
bacteremia patients with quinolone-resistant strains.
Therefore, we need to carefully consider antibiotics use in
patients with SM bacteremia who have these predictive
factors.
Additional file
Additional file 1: Table S1. Clinical characteristics of polymicrobial
infection groups. (DOCX 22 kb)
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